Moderna reports fourth quarter finacial results.

Moderna reported a surprise profit in its Q4 and FY 2023 financial results, posting fourth-quarter revenues of $2.8bn and a net income of $217m. Full-year revenues reached $6.8bn, with a net loss of $4.7bn largely due to non-cash charges. Despite lower vaccine sales, Moderna reaffirmed its 2024 product sales forecast of approximately $4bn and expects regulatory approvals for its investigational RSV vaccine for older adults beginning in the first half of 2024, with additional key milestones from its late-stage pipeline this year.

February 21, 2024
23 Articles

Further Reading